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Abstract: The ‘translationally controlled tumour protein’ TCTP was originally discovered 30 years ago by researchers interested in proteins regulated at the translational level. Cloning and sequencing confirmed the conservation of this protein
among all eukaryotic kingdoms, but did not reveal any functional clue, and TCTP was listed in the databases as a ‘family’
of its own. The functional characterisation of this protein extended over more than a decade, leading to a plethora of individual functions and interactions that have been ascribed to this protein. A major addition to the functional characterisation of TCTP was the identification in 1995 of its histamine releasing factor (HRF) activity in allergic conditions, which
for the first time described an extracellular activity for TCTP in human disease. This triggered a host of additional publications aimed at characterising this HRF activity, which are discussed in other articles of this issue. Another milestone in
the elucidation of TCTP’s function was the demonstration of its anti-apoptotic activity in 2001. Evidence is also accumulating for a role of TCTP in the cell cycle and in early development. This article provides an overview of the main cellular
activities of TCTP. The second part will summarise our current knowledge on the mechanisms involved in regulating intracellular TCTP levels.
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INTRODUCTION
1. The Translationally Controlled Tumour Protein TCTP
- History of Discovery
The first reports on the translationally controlled tumour
protein TCTP date back about 30 years. The protein was
discovered independently by three groups studying proteins
that are regulated at the translational level of gene expression. George Thomas investigated proteins that are regulated
in response to mitogenic stimulation of mouse fibroblasts
and identified a translationally controlled protein ‘Q23’ [1].
The group of George Brawerman (Boston) studied mRNAs
that are abundantly represented in untranslated, nonribosomal mRNP particles, and among these identified the
mRNA for a protein they called ‘P21’ [2]. In Heinz Bielka’s
group (Berlin) the protein ‘P23’ was found to be preferentially synthesized in exponentially growing vs. serumstarved Ehrlich ascites tumour cells [3]. The first cDNA sequences of the mouse [4] and human [5] protein where published around this time, and in the latter paper, the protein
was termed ‘translationally controlled tumour protein’, since
it was cloned from a human mammary tumour. The additional designations ‘histamine releasing factor, HRF’ [6] and
‘fortilin’ [7] were proposed later by the groups who discovered the histamine release and anti-apoptotic activities of
*Address correspondence to this author at the Graduate School of Medicine,
University of Wollongong, Wollongong, NSW 2522, Australia;
Tel: +61-2-4221-5138; Fax: +61-2-4221-4341;
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TCTP, respectively. However, since these terms relate only
to a specific activity of this multifunctional protein, the
older, more unspecific name TCTP is still being used at
large.
2. Molecular Structure and Conservation of TCTP
The cloning and sequencing did not provide any clue
about the functional importance of TCTP, since no similarity
to other proteins or functional domains was discovered, and
thus the protein was listed as a ‘family’ on its own in the
databases. As more and more TCTP sequences were deposited in the database, it became clear that TCTP is highly conserved among all eukaryotic kingdoms (reviewed in [8]). For
a recent detailed sequence comparison and phylogenetic
analysis see Hinojosa-Moya et al. [9].
Elucidation of the first 3D structure of the TCTP from
the fission yeast S. pombe [10] demonstrated that the TCTP
molecule consists of three distinct domains, the core -sheet
domain, an -helical domain and a flexible loop structure
(Fig. 1). Many additional TCTP structures subsequently deposited in databases, confirmed that this principal structure is
highly conserved in evolution. The first NMR structure
analysis also revealed the similarity of the highly conserved
-sheet domain of TCTP with Mss4/Dss4 proteins, which
bind to the GDP/GTP-free form of Rab proteins [10]. This
discovery indicated that TCTP might be related to GTPaseassociated proteins and two examples of such functional
activity will be discussed below.
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ently differing results might be reconciled, if there is more
than one binding site for Ca++ in the TCTP molecule. However, more studies will be necessary to resolve this question.
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Flexible loop

• Interaction with the Cytoskeleton

Helical domain
Helical domain

The first intracellular function described for TCTP, i.e.
microtubule binding and stabilisation, was unveiled by our
laboratory [14]. We demonstrated that TCTP (P23) associates with microtubules in a cell cycle-dependent manner. We
identified the tubulin binding domain of TCTP, which is
largely identical with the -helical domain of the 3D structure (Fig. 1). Overexpression of TCTP resulted in growth
retardation of cells, microtubule stabilisation and alteration
of cell morphology.
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core
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Fig. (1). Three-dimensional structure of the TCTP protein. The
ribbon structure of fission yeast TCTP as originally published by
Thaw et al. [10] is shown (PDB: 1H6Q). The domain structure is
indicated. The -stranded core domain is shown in yellow, and the
-helical domain region is marked in blue. The most conserved
residues are labelled in red or magenta. Green indicates the positions of the serine residues phosphorylated by the mitotic kinase
Plk-1 [19].

This is the only indication of a functional activity, which
arose from structural studies of TCTP. However, a plethora
of additional functional activities has been described since
by numerous research groups. It is the aim of this article to
provide a current overview on the many molecular associations and cellular functions of TCTP, as well as on the
mechanisms involved in the regulation of cellular TCTP levels.
CELLULAR FUNCTIONS OF TCTP
1. Interaction of TCTP with the Cytoskeleton and its
Role in Cell Division
• TCTP – A Non-Canonical Ca ++-Binding Protein
One of the earliest demonstrations on a functional activity for TCTP was the report on the Ca++-binding activity of
trypanosome TCTP by Haghigat & Ruben [11]. Since then,
many groups have demonstrated Ca++-binding of TCTP by
means of the Ca++-overlay assay (see e.g. [12]), even though
the TCTP sequence does not harbor a canonical Ca++-binding
motif.
In 2007, two detailed studies have been published aimed
at characterising the Ca++-binding site in TCTP. Feng and
co-workers [13] used multi-dimensional NMR spectroscopy
to determine the solution structure of human TCTP and to
identify the Ca++-binding site. They concluded that the weak
binding site involves the residues N131, Q132 and D150,
located in the -stranded core domain close to the connection
with the -helical domain. In contrast, Graidist et al. [12]
employed a combination of several methods to study the
Ca++-binding activity of TCTP. They performed a detailed
mutational analysis, leading them to conclude that the residues E58 and E60, located in the floppy loop of the TCTP
structure, are involved in Ca++-binding. These two appar-

A recent, more detailed study into the interaction of
TCTP with the cytoskeleton revealed that TCTP also interacts with actin filaments; it localises to a subset of actin-rich
fibers in migrating cells [15]. This observation is corroborated by another report on a domain in TCTP, similar to the
actin-binding domain in cofilin [16]. Bazile et al. [15] also
demonstrated that TCTP’s interaction with the microtubules
is transient, and that it does not behave as a bona-fide microtubule-associated protein.
• Binding to the Mitotic Spindle and Mitotic Phosphorylation of TCTP
In our study we reported that TCTP (P23) is bound to the
mitotic spindle, but is detached from the spindle during
metaphase-anaphase transition [14]. TCTP binding to the
spindle, predominantly to the poles, has since been confirmed by reports from other laboratories [17,18]. It is anticipated that TCTP is involved in stabilising spindle microtubules [17,19], and the observed detachment of TCTP from
the spindle might be important for the metaphase-anaphase
transition. We also observed that TCTP is subject to mitotic
phosphorylation (M. Lee, Y. Gachet and U.A. Bommer, unpublished results), and we anticipated that this phosphorylation event is necessary for the detachment of TCTP from the
spindle microtubules. The protein kinase involved in TCTP
phosphorylation was subsequently characterised by Yarm
[19] as the mitotic polo-like kinase Plk-1. He also identified
two phosphorylation sites for Plk-1 in the flexible loop of the
TCTP structure (Fig. 1). Expression of a TCTP protein mutated in these sites led to severe disturbance of mitotic progression and to the formation of multinucleated cells. The
phosphorylation of TCTP by Plk-1 has since been studied by
another laboratory [20], and it has been proposed as a marker
for the action of anti-cancer drugs, targeting Plk-1 [21].
• TCTP as a General Mitotic Regulator
There is an increasing body of evidence indicating that
TCTP is indeed an important mitotic regulator, and mechanisms other than stabilisation of spindle microtubules have
been proposed to play a role in this activity. A range of nuclear proteins involved in mitotic progression have been reported to interact with TCTP, and either to regulate TCTP
levels or being regulated by TCTP.
Chfr is a checkpoint protein that plays an important role
in cell cycle progression. Burgess et al. [17] demonstrated
that lowly expressed ectopic Chfr is localised in the cytoplasm, but localises to the spindle during mitosis. They also
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showed that Chfr interacts with TCTP throughout the cell
cycle, unless cells are treated with microtubule-destabilising
agents. Two separate reports by Johansson et al. [22, 23]
describe the interaction of TCTP with the two nuclear proteins, nucleophosmin and nucleolin, in embryonic stem cells.
In the case of nucleophosmin, the interaction was shown to
be independent of phosphorylation by Plk-1.
A recent paper unveiled a novel pathway, through which
TCTP is likely to be involved in the dysregulation of mitotic
progression in hepatocellular cancer, HCC [24]. The authors
identified the TCTP gene, tpt1, as a target for transcriptional
activation by CHD1L, a specific oncogene frequently
upregulated in HCC. Overexpression of TCTP promoted the
ubiquitin-proteasome degradation of the phosphatase
Cdc25C. During mitotic progression, Cdc25C is essential for
the final activation of Cdk1. The drop of Cdk1 activity induced by TCTP overexpression resulted in a too fast mitotic
exit and consequently led to chromosome miss-segregation.
The effect of TCTP overexpression on mitotic progression in
tumour cells described here are consistent with earlier papers
reporting that over- or underexpression of TCTP affects the
duration of the cell cycle [14, 23, 25]. The observation that
TCTP is one of the proteins ubiquitinylated and partially
degraded in proteasomes during mitosis [18] would also indicate that tight regulation of TCTP levels is essential for the
orderly exit of cells from mitosis.
It is well documented from plants [25, 26], as well as
from lower animals, such as cnidarians [27], that TCTP is
preferentially expressed in meristmatic/proliferative active
tissues, and recently, a thorough study described TCTP as a
general mitotic regulator in plants and animals [25]. This
group demonstrated that TCTPs are interchangeable between
plants (Arabidopsis) and animals (Drosophila) in their ability to rescue mitotic defects in the other species.
• Importance of TCTP in Early Development
The involvement of TCTP in mitotic regulation indicates
that it could play a role in the early development of animals
and plants. There are several lines of evidence clearly supporting this view:
1.

Complete gene knockout of TCTP in Drosophila [28]
and in mice [29-31] is embryonic lethal, and this effect was related to excessive apoptosis during early
embryonic development of these mice. Koide et al.
[31] provided data showing that TCTP functions as an
inhibitor of the BMP pathway in the early phases of
development.

2.

In 2007, two papers reported a role for TCTP in the
reprogramming of somatic cell nuclei to an embryolike gene expression pattern after transplantation into
oocytes [32,33]. In this process, the transcription factor oct4, which is also considered a stem cell marker,
is massively up-regulated. Koziol et al. [32] identified
TCTP as one of the proteins that bind to the regulatory
region of the mouse oct4 gene and that activates its
expression and hence the activation of genes involved
in pluripotency. As mentioned in the previous section,
TCTP was described as interaction partner for nucleolin [22]. This paper also demonstrated that nucleolin
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interacts with the transcription factor oct4 in human
and murine embryonic stem cells.
3.

Several reports indicate that TCTP plays a crucial role
in early gametogenesis. Guillaume et al. [34] found
high expression levels of TCTP in most stages of
spermatogenesis, and Vitale et al. [35] showed that
TCTP expression is altered during murine oocyte
maturation. Meyvis and coworkers [36] reported that
knock-down of TCTP in C. elegans reduced the numbers of eggs laid by the hermaphrodite in the F(0) and
F(1) generations, indicating a pivotal role of TCTP in
egg production.

4.

A critical process in early mammalian development is
the implantation of the fertilised egg. A recent publication reports that TCTP mRNA and protein levels
increase in the uterus of mice during early pregnancy,
reaching a peak at D5, but then decrease dramatically
to D7 [37]. The peak of TCTP expression coincided
with the implantation phase, and at this time TCTP
levels were considerably lower in the uteri of pseudopregnant control mice. The number of implanted embryos was reduced when TCTP levels were downregulated by injection of antisense oligos. Arcuri et al.
[38] described a role for TCTP in Ca++-handling and
transport in the placenta. TCTP knock-down was associated with reduced cellular calcium-uptake and
buffering capacity.

5.

In plants, knockout of TCTP leads to a male gametophytic phenotype, with normal pollen formation and
germination, but impaired pollen tube growth [26]. Silencing of TCTP by RNA interference slowed vegetative growth, and leaf expansion was reduced because
of a smaller cell size. These data indicate that TCTP is
also important for plant cell growth and development.

2. Part of the Cell’s Survival Kit: The Anti-Apoptotic
Protein TCTP
• Protection Against Diverse Cell Stresses
TCTP was originally described as a growth-induced protein (see section on TCTP and growth regulation below), and
later it became clear that it is also highly regulated in response to a range of additional cellular stimuli and stress
conditions. Examples of stress-dependent regulation of
TCTP levels will be detailed in the regulation section below.
Here, I will summarise the various mechanisms in discussion
to-date, by which TCTP may exert its cyto-protective function.
• A Role for TCTP in Ion-Homeostasis: Regulation of the
Na+-K+-ATPase
A potential role of TCTP in the regulation cellular ion
homeostasis was revealed by Kyunglim Lee’s group in
Seoul. Using a yeast two-hybrid screen, they established that
TCTP interacts with the 3rd large cytoplasmic domain of two
isoforms of the Na+-K+-ATPase [39]. They also showed that
overexpression of TCTP resulted in inhibition of the enzyme. The Na+-K+-ATPase had been implicated in the
pathogenesis of hypertension, and the authors hypothesised
that overexpression of TCTP might promote the development of hypertension. They generated TCTP overexpressing
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mice, which indeed developed systemic arterial hypertension, about six weeks after birth [40].
• Anti-Apoptotic Properties of TCTP (Fortilin)
The first demonstration of the anti-apoptotic function of
TCTP came from Fujise’s laboratory in Houston [7]. Importantly, these authors demonstrated that overexpression of
TCTP protected HeLa cells from undergoing etoposideinduced apoptosis. Based on their observations, they coined
the name ‘fortilin’ for this protein and since refer to it under
this name. Anti-apoptotic activity of TCTP has since been
reported in numerous papers and for a range of cellular conditions. Here, I will give a few of the recently published examples:
Gnanasekar et al. [41] showed that human TCTP and its
homologue from the parasite Schistosoma mansoni may act
as a molecular chaperone under heat shock conditions, protecting other proteins against thermal denaturation. Several
groups reported regulation of TCTP levels under Ca++-stress
conditions [42-44], and overexpression of TCTP partially
protected cells from induction of apoptosis by Ca++-stress
[12,42]. The importance of TCTP as a survival factor, involved in the development of cellular resistance against anticancer drugs was demonstrated earlier for etoposide [7] and
5-fluorouracil [45].
The role of TCTP in protecting cells against oxidative
stress was demonstrated through cloning of genes that confer
such protection to NIH-3T3 cells [46]. Gnanasekar et al. [47]
reported that TCTP of the parasite Brugia malayi functions
as an antioxidant protein. More recently, Lucibello et al. [48]
studied the importance of TCTP in the protection of cancer
cells against oxidative stress, and showed that it is an important survival protein likely to be involved in the resistance
against anti-cancer therapy. Interestingly, this paper also
reports that glucose deprivation resulted in down-regulation
of TCTP, followed by cell death. The latter finding is corroborated by our recent study on pancreatic beta-cells, showing that an exposure to high glucose (25 mM) leads to an
increase in intracellular TCTP levels [43]. This paper also
demonstrated that overexpression of TCTP partially protects
beta-cells against the induction of apoptosis by high levels of
saturated fatty acids (palmitate), a particular stress situation
for these cells.
The role of TCTP as an anti-apoptotic protein was highlighted in TCTP gene-knockout studies on mice [29-31],
which demonstrated embryonic lethality due to excessive
apoptosis at an early embryonic state. In 2009 two papers
showed the importance of TCTP in preventing apoptotic cell
death for the maintenance and development of T-cells. Using
conditional TCTP knockout mouse models, Wu and colleagues [49] demonstrated that TCTP is essential for the viability of mature peripheral T-cells. Xiong et al. [50] reported that IL-2 promotes the survival of regulatory T-cells
through stimulation of TCTP expression.
• Mechanisms of Anti-Apoptotic Activity
TCTP has been shown to interact with two other antiapoptotic proteins of the Bcl-2 family, i.e. Mcl-1 [51, 52]
and Bcl-XL [53]. Bcl-XL and TCTP have both been implicated in maintaining the survival of murine T-cells during
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activation [53]. Two reports indicate that Mcl-1 and TCTP
stabilise each other, with TCTP being stabilised by Mcl-1
[52] but also vice versa [51]. Yet another paper showed that
they exert their anti-apoptotic function independent of each
other [45].
A range of mechanisms have been proposed as to how
TCTP exerts its anti-apoptotic activity. Graidist et al. [12]
demonstrated a role of TCTP as a Ca++-scavenger, preventing excessive increase in intracellular Ca++-levels in Ca++stress conditions. Gnanasekar and colleagues reported that
TCTP acts as molecular chaperone under heat shock conditions [41]. Telerman’s group [30] proposed a novel mechanism, according to which TCTP, with its helical domain,
inserts itself into the mitochondrial membrane, thereby antagonising the dimerisation of the pro-apoptotic protein Bax
and preventing the Bax-induced increase of mitochondrial
membrane permeability. A cell stress-dependent association
of TCTP with mitochondria has been previously observed in
yeast [54].
A peculiar involvement of TCTP in anti-apoptotic intercellular signalling was recently proposed by Sirois and coworkers [55]. This paper reports that TCTP is one of the
marker proteins present at the surface of the nanovesicles
released from apoptotic endothelial cells. These nanovesicles, which are different from apoptotic blebs, induce an
anti-apoptotic phenotype in vascular smooth muscle cells
(VSMC). Pre-treatment of endothelial cells with TCTP
siRNAs attenuated the anti-apoptotic activity of purified
nanovesicles on VSMCs.
• Antagonism Between TCTP and P53
Antagonism to the tumour suppressor protein p53 has recently been proposed as an another mechanism by which
TCTP can prevent apoptotic cell death. It is not surprising,
that activation of p53, one of the most powerful proapoptotic proteins, down-regulates the anti-apoptotic protein
TCTP. Such observations have been made earlier, using a
temperature sensitive mutant of p53, in two quite different
cellular systems [42,56]. Several recent studies now describe
TCTP as an interaction partner and antagonist for p53, albeit
by differing mechanisms. Rho et al. [57] showed that overexpression of TCTP in lung carcinoma cells reversed p53mediated apoptosis, whereas TCTP knock-down increased
apoptosis. Similarly, Chen and colleagues [58] observed
TCTP (fortilin) interaction with p53 using GST-pull down
assays; they showed that TCTP inhibits p53-dependent apoptosis. However, these two studies arrive at differing conclusions in the following two points: 1. In the mapping of the
domain in TCTP that is involved in p53 binding: Rho et al.
[57] found that an internal domain (corresponding to the helical domain; Fig. 1) is involved in p53 binding, whereas
Chen et al. [58] observed that the N- and C-terminal parts of
the molecule (the -sheet domain; Fig. 1) participate in this
interaction. 2. In the mechanism by which TCTP antagonises
p53: Rho et al. reported that TCTP is destabilising p53 in
lung cancer cells, whereas Chen and colleagues did not observe p53 destabilisation, but instead proposed that TCTP
blocks p53-induced transcriptional activation of Bax [58].
A profound study on this issue has just been published by
the Telerman group [59]. They describe details of a negative
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feedback loop between P53 and TCTP, according to which
TCTP promotes MDM2-mediated ubiquitination and degradation of P53. Conversely, P53 directly represses TCTP
transcription. This paper also provides evidence for the implication of this antagonism to P53 in cancer, which will be
discussed below.
3. Involvement of TCTP with Growth Regulation and the
Translational Machinery
• TCTP and Cell Growth Regulation
Translational induction of TCTP synthesis upon growth
stimulation of mammalian cells was one of the earliest observations about this protein [1, 3]. We typically observed an
about four-fold increase of TCTP levels after growth induction of mouse fibroblasts [60]. Growth-dependent regulation
of TCTP synthesis has been observed by many groups, as
reviewed in our earlier article [8]. In the last decade, an
overwhelming body of evidence has associated TCTP with
cancer, as will be discussed below. A detailed study on
TCTP in Arabidopsis thaliana demonstrated that knockdown of this protein generated serious growth defects [26],
highlighting the importance of TCTP as a growth regulator,
also in plants.
All these observations reflect a positive association with
cell growth, however the question remains unanswered:
What is the underlying mechanism, by which TCTP positively affects cell growth? It is attractive to speculate that
TCTP’s involvement in mitotic regulation might be important. However, we observed that overexpression of TCTP
actually slows cell cycle progression [14], and very recently
Chan et al. [24] showed that increased TCTP induces mitotic
defects and chromosome miss-segregation in hepatocellular
carcinoma. Thus, it appears that controlled expression of
TCTP is essential for an orderly transition through the cell
cycle, making it unlikely that mass induction of TCTP levels
are required for progression through mitosis.
Two studies reported that an increase in TCTP levels results in activation of cell growth signalling pathways: Kim et
al. [61] found that in HeLa cells, TCTP overexpression resulted in activation of several growth signalling pathways,
inclusive of tyrosine phosphorylation of the EGF receptor,
phosphorylation of PLC-, as well as activation of the
Ras/Raf/ERK and the PI3K/Akt pathways. Specific inhibition of the PI3K/Akt pathway significantly decreased TCTP
overexpression-induced cell survival, whereas inhibition of
PLC- pathway diminished TCTP overexpression-induced
cell migration. In a more recent study, the same group performed similar experiments on human breast epithelial cells
[62]. They found that TCTP induces release of the protein
kinase Src from the Na+-K+-ATPase. Src activation then resulted in tyrosine phosphorylation of epidermal growth factor receptor and the activation of a range of signalling pathways, such as the PI3K/Akt, the MAP kinase, and the PLC-
pathways, apart from other cellular alterations. Conversely,
Wang and Dao [63] reported that TCTP is down-regulated
during neural differentiation of mouse embryonic stem cells.
The regenerating rat liver after partial hepatecomy is a
classical model for tissue growth. Zhu et al. [64] studied
TCTP mRNA expression in this model and demonstrated
that TCTP mRNA levels were significantly up-regulated in
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the period from 3 to 12 hours after partial hepatectomy, but
then decreased at 24 hours before returning to original levels.
Cell growth is intimately linked with an increase in protein synthesis, and early observations demonstrated that both
protein synthesis and ribosome biogenesis are largely increased after partial hepatectomy. Several other observations
also potentially link TCTP with the translational machinery
and its regulation; these will be discussed in the following
section.
• Is TCTP an Upstream Regulator of the mTOR Signalling Pathway?
The mammalian target of rapamycin complex 1
(mTORC1) signalling pathway is a major regulator of protein synthesis in mammalian cells [65]. This pathway represents a complex signalling network, which integrates a range
of positive and negative input signals and positively regulates protein synthesis, as well as other anabolic pathways.
Most relevant for the regulation of protein synthesis is the
regulation of mTORC1 in response to growth factor signalling, to amino acid availability and to the energy status of the
cell.
An important upstream activator of mTORC1 is the small
GTPase Rheb (Ras homologue enriched in brain), which in
turn is negatively regulated by its GTPase-activating protein,
the tumour suppressor protein TSC1/TSC2. The guanosine
nucleotide exchange factor (GEF) for Rheb remained for
long time (and still is) enigmatic. In 2007, Hsu et al. [28]
published a paper describing TCTP as a potential GEF for
Rheb. They presented data indicating that reducing Drosophila TCTP (dTCTP) levels reduced cell size, cell number
and organ size, resembling dRheb mutant phenotypes. They
also found that dTCTP directly associates with dRheb and
can act as a GEF for Rheb. Thus, this paper ascribed an important role to TCTP, as a positive regulator of the TOR
growth signalling pathway.
The idea that TCTP acts as a GEF for small GTPases,
such as Rheb, appeared attractive based on TCTP’s structural similarity to MSS4/DSS4 proteins, which are known to
bind to the Rab family of GTPases [10]. However, subsequent investigations aimed at confirming TCTP’s importance
in regulating mTORC1 signalling in mammalian cells failed
to support the findings published for Drosophila TCTP: We
observed that reducing TCTP levels did not reproducibly
affect mTORC1 signalling in HEK 293 cells [66]. Moreover,
overexpression of TCTP did not rescue mTORC1 signalling
in amino acid-starved cells, and no stable interaction between TCTP and Rheb or mTORC1 was observed. Similarly,
Rehmann et al. [67] were unable to detect GDP exchange
activity of TCTP towards Rheb. TCTP depletion in cells did
not affect direct downstream targets of Rheb, and no interaction between TCTP and Rheb could be detected by NMR
spectroscopy. However, another study reported a weak binding between Rheb and TCTP, and also a GEF activity for
TCTP towards Rheb [68]. These authors also performed further structure modelling in support of the interaction. –
Overall, this issue is still controversial. We are aware, from
personal communications, that other laboratories also obtained negative results in this regard, which have not been
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Table 1. TCTP Expression in Cancer Cell Lines
Cells Derived From
Colon cancer

Cell Lines

Result Regarding TCTP

Reference

SNU-C4, C5

mRNA levels 2 - 4.5 fold increased compared to normal cells

[109]

Colon cancer

LoVo-cells

TCTP knock-down results in decreased cell proliferation, migration,
invasion and tumorigenicity.

[81]

Prostate cancer

LNCaP

TCTP knock-down results in decreased cell viability and increased apoptosis

[79]

Bronchial epithelia (transformed)

1170-I, 1198, 

TCTP secretion is two-fold higher in transformed vs. non-transformed cells.

[75]

Reduction of TCTP levels leads to reduced tumorigenicity in mice
and reversion from the malignant phenotype.

[56]

(non-transformed)

BEAS-2B, 1799

Human leukaemia

U937, K562

Breast carcinoma

MDA-MB231S
BT20, T47D

Colon cancer
Lung cancer
Melanoma

DLD-1
A549
various lines

Multiple Myeloma

RPMI8226

Cell clones reverted from the transformed to the normal phenotype display
lower TCTP expression.

[77]
[78]

published. Therefore, currently this potentially interesting
function of TCTP remains an unresolved question.

More work is required to determine, which potential role
TCTP might play in protein synthesis.

• Is TCTP Part of the Translational Apparatus and a
Downstream Target of mTOR?

4. Is TCTP a Tumour Protein?

The mRNA for TCTP starts with a 5’-terminal
oligopyrimidine tract (5’-TOP) [69]. This observation
suggests that TCTP expression may be subject to translational control via the mTORC1 signalling pathway. Almost
all mRNAs that bear this signature encode proteins that are
part of the translational apparatus, and they are known to be
translationally up-regulated through mTORC1 [65]. It therefore seems likely that TCTP mRNA is a downstream target
of mTOR (see TCTP regulation; below).
Direct evidence for a role of TCTP in the translational
machinery came from a study by Cans et al. [70]. Using a
yeast two-hybrid search, they identified TCTP as a binding
partner for protein synthesis elongation factor eEF1A, and its
guanine nucleotide exchange factor, eEF1B. The interaction of TCTP with eEF1B was also confirmed by Langdon
et al. [71]. Cans and colleagues demonstrated that TCTP
preferentially stabilizes the inactive GDP-bound form of
eEF1A, by impairing the GDP exchange reaction promoted
by eEF1B. From this study, it would appear that TCTP acts
as a negative regulator for eEF1A, which is apparently inconsistent with a growth-promoting role of TCTP.
A more recent report provided an interesting twist to this
story: Leclerq et al. [72] performed a study on Sphingosine
kinase 1 (SK1), which catalyses the formation of the phospholipid sphingosine 1-phosphate. Elevated activity of this
enzyme enhances cell proliferation and survival, and is implicated in tumorigenesis. This group had previously shown
that eEF1A interacts with and activates SK1. In this study,
they demonstrate that it is [eEF1A x GDP], but not [eEF1A x
GTP], that activates SK1 activity in vitro. They also show
that enhancing cellular [eEF1 x GDP] levels through expression of TCTP (which acts here as guanine nucleotide dissociation inhibitor of eEF1A) increases cellular SK1 activity.
In this way, TCTP could be implicated in tumorigenesis,
even though being a negative effector of protein synthesis.

• TCTP Expression in Human Tumours
The observation that TCTP is expressed in nearly all cell
types and tissues, albeit at differing levels [73] initially
raised some doubts on the justification of the term ‘tumour
protein’ [74]. However, over the past decade, a substantial
body of evidence has accumulated, demonstrating that TCTP
is positively related to cancer: First, several studies on cancer
cell lines, derived from a range of cancer types, have shown
that TCTP levels are positively related to properties of these
cells relating to growth behaviour, anti-apoptotic properties
and tumorigenicity (Table 1). Second, studies on several
human cancers have demonstrated that TCTP levels are upregulated in most, but not all, of the investigated cancer
types (Table 2). In some cases, such as lung cancer [75],
hepatocellular carcinoma [24] and breast cancer [59], TCTP
has even been proposed to be suitable as a tumour marker.
Our recent data obtained by immunohistostaining of human
colon cancer samples also indicate that TCTP levels are
significantly increased in adenomas and adenocarcinomas of
the colon, compared to normal colon tissue (M. Radojkovic,
P. Colligan, P. Puri, A. Lochhead, M. Aghmesheh & U.
Bommer, unpublished results).
•

TCTP in the Tumour Reversion Model

The importance of TCTP in cancer has been convincingly demonstrated through studies using the tumour reversion model. This model is based on the rare event of tumour
cells reverting back from the malignant to the normal phenotype (reviewed in [76]). Telerman’s group studied this system intensively and identified a number of genes that are
particularly involved in this process, of which TCTP appears
to play a major role. In particular, they showed that inhibition of TCTP expression by siRNA results in suppression of
the malignant phenotype [56]. They also demonstrated: (1.)
that revertants derived from melanoma cell lines, colon or
lung cancer show decreased TCTP levels; (2.) that inhibition
of TCTP expression by antisense DNA led to a ‘flat rever-
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Table 2. TCTP Levels in Human Cancers
Cancer Types
Colorectal and lung cancer;
Oesophageal, hepatocellular, pancreatic cancer

TCTP Levels

Method/Comment

Reference

up-regulated
not altered

Proteomics studies on tissues and
body fluids

[110]

usually up-regulated

Western blot of cell lysates

[75]

Serum of lung cancer patients vs. serum of healthy controls about 2.3-fold up-regulated

Western blot; densitometry

[75]

Breast cancer vs. surrounding tissue

up-regulated

Proteomics study

[111]

Breast cancer

high TCTP associated with aggressive tumours;
Immunohistochemistry
poor prognosis

Six Lung SSCs vs. normal tissue;
Five Lung adenocarcinomas

Tumours of liver, lung, thyroid, larynx,
skin, uterus, breast, ovary, prostate, rectum,
Tumours of cervix, pancreas, stomach, testis

up-regulated

Liver cancer vs. adjacent normal tissue
Hepatocellular carcinoma
Colorectal cancer (20 tumour samples)

[59]

Western blot of cancer samples
vs. normal tissue

[56]

up-regulated

mRNA levels by RT-PCR analysis

[64]

up-regulated in most of the advanced tumours

Immunohistochemistry

[24]

2.0-fold up-regulated

mRNA levels by microarray;
by real-time PCR

[112]

not up-regulated

1.2-fold up-regulated

sion phenotype’ of transformed NIH3T3 cells and (3.) that
reduction of TCTP levels raised the number of spontaneous
revertants dramatically [77]. These results were corroborated
by a recent study using a proteomics approach to identify
proteins altered in tumour reversion in multiple myeloma
cells. This group reported that, among others, STAT3,
TCTP, CDC2 and PCNA are down-regulated in the tumour
reversion process [78].
• Mechanisms Through which TCTP Could Promote
Cancer
The most obvious way, by which TCTP is likely to promote cancer, is through its anti-apoptotic activity. In analogy
to many other anti-apoptotic proteins, such as Bcl-2, Mcl-1
or Bcl-XL, overexpression of TCTP is part of the armoury of
cancer cells to evade apoptosis. For example in LNCaP prostate cancer cells, decreased expression of TCTP was associated with reduced cell viability [79]. Similarly, Lucibello et
al. [48] demonstrated that cell clones with forced TCTP expression, derived from the breast cancer cell line MDA-MB231, displayed reduced sensitivity to oxidative stress,
whereas cells with down-regulated TCTP showed increased
sensitivity.
Another study also underscored the importance of preventing apoptosis for the role of TCTP in cancer. Lee et al.
[80] established that TCTP (fortilin) interacts with transforming growth factor-beta stimulated clone-22 (TSC-22).
Overexpression of TCTP in ovarian carcinoma cells resulted
in increased degradation of TSC-22 and the reversal of TSC22-mediated apoptosis, whereas knockdown of TCTP led to
an increase in apoptosis in these cells.
The antagonism between TCTP and the tumour suppressor protein P53 is likely to play a considerable role in
TCTP’s ability to promote cancer. Substantial evidence for
this conclusion has been provided in the recently published
paper by Amson et al. [59]. These authors found that in
about 500 breast cancer patients, a high-TCTP status is associated with aggressive tumours, and predicts a poor progno-

sis. Also, TCTP knockdown in primary mammary tumour
cells from ErbB2 transgenic mice resulted in increased P53
expression and a decreased number of stem cell-like cancer
cells.
Ma et al. [81] investigated the effect of TCTP knockdown on proliferation, migration, and invasion properties of
colon adenocarcinoma cells. They used 2D gel electrophoresis to identify proteins, whose expression levels are altered
after TCTP knockdown and found that components of the
ubiquitin-proteasome system, proteins involved in the biosynthesis of cytoskeletal proteins and in tumour metastasis
were altered upon TCTP removal.
Another recent study, on human hepatocellular carcinoma cells [24], proposed a different mechanism of TCTPdependent tumorigenesis. These authors studied the mode of
action of the chromodomain helicase DNA binding protein1like (CHD1L), which is amplified and acts a specific oncogene in >50% of human hepatocellular carcinomas (HCC)
and found that CHD1L targets the transcription of the TCTP
gene tpt1. Overexpression of TCTP was found in about 41%
of human HCC samples, and it highly correlated with the
advanced tumour stage of HCC patients. Further investigations revealed that the tumorigenicity of TCTP is linked to a
role in mitotic regulation, as described earlier. TCTP induces
a faster mitotic exit and chromosome miss-segregation, resulting in chromosome instability.
Thus, these two recently published studies describe two
important, but quite different mechanisms of TCTPdependent cancer development. Amson et al. [59] emphasise
the importance of TCTP-dependent P53 degradation using
the example of breast cancer, whereas Chan et al. [24], for
hepatocellular carcinoma, describe a novel mode of action of
TCTP, based on its role in mitotic cell cycle regulation. A
common underlying mechanism appears to be the promotion
by TCTP of the ubiquitin-proteasome degradation of proteins crucial for cellular homeostasis or cell cycle progression. In this context, the finding by Ma et al. [81] is interest-
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ing, that after knock-down of TCTP the expression of components of the ubiquitin-proteasome system is altered.
• Is TCTP Suitable as an Anti-Cancer Drug Target?
The multiple roles/mechanisms described so far for
TCTP-dependent tumorigenicity provoke the question of
whether TCTP is or can be made a suitable drug target in
anti-cancer treatment. Whilst, to my knowledge, no report
directly addressing this question has been published as yet,
there are a couple of papers touching on this important point.
In model studies on prostate cancer cells Gnanasekar et al.
[79] showed that transfection with TCTP siRNA reduced the
viability of these cells. Yao et al. [82] performed a comparative proteomic analysis to survey changes in protein expression levels after treatment of three colon cancer cell lines
with the anti-cancer drug oxaliplatin. TCTP was among the
21 proteins found to be altered in all three cell lines. Its expression was significantly up-regulated within 24 h, but then
gradually decreased from 48 to 72 h. Tuynder and colleagues
[77] tested a panel of drugs for their ability to suppress
TCTP protein levels in U937 cells, and it appeared that this
ability correlated well with the potency of these drugs to
induce cytotoxicity in these cells. Taken together, these observations would suggest that TCTP might be suitable as a
biomarker in testing the drug efficacy in cellular anti-cancer
drug testing.
The suitability of TCTP as direct anti-cancer drug target
has been reported for three drugs. Since the earlier discovery
of Plasmodium TCTP as a potential target for the antimalarial drug artemisinin [83], the interaction of TCTP with this
drug has been investigated in more detail [84]. Artemisinin is
also considered as an anti-cancer drug [85], and Fujita et al.
[86] published a study on the interaction of human TCTP
(fortilin) with dehydroartemisinin (DHA). They demonstrated that DHA binds to human TCTP and decreases cellular TCTP levels through promoting ubiquitination and proteasome-dependent degradation. In their recent article on the
antagonism between TCTP and P53, Amson et al. [59] report the targeting of TCTP by the pharmacological compounds sertraline and thioridazine, which interfere with the
down-regulation of P53 by TCTP.
Taken together, the wide range of observations summarised in this section, provides a solid justification for the
term ‘tumour protein’ in the name of TCTP.
REGULATION OF CELLULAR TCTP LEVELS
1. Cell Physiological Conditions Resulting in Regulation
of TCTP Levels
There is a wealth of publications reporting changes of
TCTP levels in response to alterations of cell physiological
conditions. Many of the groups now working on TCTP discovered this protein through such type of observations. It
would be beyond the scope of this article, to comprehensively review all these reports. This section will briefly
summarise the main types of extracellular signals that lead to
regulation of TCTP levels.
• Growth Signals and Nutrients
As pointed out above, the induction of TCTP synthesis
by cell growth signals is well documented (reviewed in [8]).
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Many of these studies used growth stimulation of serumstarved cells and foetal calf serum as general source of
growth factors, whereas only few studies investigated the
potential of individual growth factors to induce TCTP synthesis. Vercoutter-Edouart et al. [87] demonstrated that in
MCF-7 human breast cancer cells, TCTP was among four
proteins up-regulated by fibroblast growth factor-2. Recently, we found that TCTP levels are increased about twofold after insulin treatment in HT29 colon cancer cells (J.
Chen & U.A. Bommer, unpublished observation). Schmidt et
al. [88] demonstrated that TCTP synthesis is induced by
phorbol ester and forskolin, both at the transcriptional and
posttranscriptional levels of gene expression, and two other
papers reported the regulation of TCTP levels through the
vitamin D receptor pathway [89, 90].
There is only sparse information about nutrient regulation
of TCTP levels. Back in 2000, Bonnet et al. reported downregulation of TCTP (together with ribosomal protein S6)
upon ammonium starvation in fission yeast. However, it is
likely that this treatment merely reflects a stress condition
rather that a genuine nutritional signal. Our recent study on
pancreatic beta-cells demonstrated that TCTP levels are subject to glucose regulation in this cell type [43].
• Cell Stress Conditions
The induction of TCTP in response to various stresses
was initially reported more than ten years ago, for mammalian cells [44, 91], as well as for worms [92] and for plants
[93]. The types of stresses known to date that result in TCTP
induction and/or down-regulation include the following
groups:
1.

Heat shock. Induction of TCTP synthesis under heat
stress conditions was originally noted in parasitic organisms, such as Trichinella [94,95] and Schistosoma
[41]. A recent study investigated the importance of
TCTP for stress tolerance of the cabbage, Brassica oleracea, and found that silencing of the TCTP gene by
RNAi led to reduced vegetative growth rate and decreased tolerance of cold, high temperature and salt
stresses by the cabbage plants [96].

2.

Oxidative stress. The first study reporting an oxidation status-dependent regulation of the TCTP gene
was published by Rupec et al. [91]. These authors set
out to clone genes that are induced under hypoxia, as
it occurs in solid tumours. They observed a 12-fold
up-regulation of a form of TCTP (P23) mRNA, fused
to the mitochondrial 16S ribosomal RNA under conditions of hypoxia. They also found that hypoxia induced up-regulation of TCTP mRNA and 16S RNA
individually in HeLa cells.
Yan et al. [97] investigated the oxidative stress response in a non-malignant breast epithelial cell line
and in a derived malignant cell line. TCTP (fortilin)
was found to be significantly up-regulated after hydrogen peroxide treatment in the transformed cells,
but not in the parental cells. Gnanasekar and colleagues [47] reported that TCTP from the filarial
parasite Brugia malayi has anti-oxidant properties.
Nagano-Ito et al. [46] found that expression of TCTP
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cDNA, confers resistance to hydrogen peroxide treatment to mouse NIH-3T3 fibroblasts. Rid and coworkers observed that in human keratinocytes, under mild
oxidative stress, TCTP translocates into the nucleus
[90].

3.

4.

A very recent study by Lucibello et al. [48] showed
that in the breast cancer cell line MDA-MB-231 the
sensitivity to oxidative stress was strongly enhanced
in cells with reduced TCTP levels, and decreased in
cells with high TCTP levels. The authors propose
TCTP as a ‘stress hallmark’ in cancer cells. The same
paper also investigated the regulation of TCTP under
oxidative stress in a range of tumour cell lines.
Depending on the severity of the cell stress, the
authors found either up- or down-regulation of TCTP
levels: In mild oxidative stress, TCTP was upregulated in cells that survived the treatment. In
contrast, severe oxidative stress caused downregulation of TCTP followed by cell death.
Generalising from these observations it would seem
that under mild stress conditions, TCTP is induced as
part of the cell’s defence system, whereas under
severe stress, pro-apoptotic mechanisms prevail,
which include the down-regulation of anti-apoptotic
proteins,
such as TCTP.
Ca++-stress. Regulation of TCTP levels in Ca++-stress
conditions has initially been studied by Xu et al. [44]
in COS-7 cells. They observed an increase in TCTP
levels under these conditions, regulated at both transcriptional and post-transcriptional levels. In contrast,
in our later study on mouse embryo fibroblasts we
found that TCTP levels are down-regulated under calcium ionophore or thapsigargin treatment [42]. Interestingly, in some cases, we also saw a moderate initial
up-regulation of TCTP levels, followed by a more
substantial down-regulation upon prolonged treatment. The conclusion drawn in the previous paragraph
from the paper by Lucibello et al. [48] would be consistent with this latter observation, and it could provide an explanation to reconcile the two apparently
contradicting results for TCTP regulation in Ca++stress [42,44]. Decrease of TCTP levels were also observed in pancreatic beta-cells upon stress induced by
treatment with thapsigargin or saturated fatty acids,
i.e. palmitate [43].
Stress induced by heavy metals. The most dramatic
alterations of TCTP levels have been observed under
exposure of cells or organisms to heavy metals. The
first paper reporting such an example investigated the
gene expression pattern of earthworms (Lumbricus
rubellus) exposed to heavy metal-infested soils from
the mining industry. It reported an at least four-fold
increase in TCTP (mRNA) levels in a earthworm
population from a Pb/Zn/Cd-polluted mine and an
even 335-fold increase in earthworms from a Cupolluted mine [92]. Schmidt et al. [88] working with
two mammalian cell lines, found that cobalt and
nickel induced TCTP expression about two- to threefold at the mRNA and protein levels, whereas copper
resulted in a five-fold induction of TCTP mRNA or
protein levels. TCTP was also identified as one of the
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proteins specifically expressed in plants that are tolerant to aluminium-stress [93].
5.

Stress induced by toxins or drugs. Oikawa et al. [98]
studied the effect of tetrachlorodibenzo-p-dioxin
(TCDD, or ‘dioxin’) on the mRNA expression patterns of mouse embryonic stem cells. The mRNA of
TCTP (HRF) was found to be up-regulated by TCDD,
which also induced the synthesis and secretion of
TCTP. Another group of toxic and carcinogenic pollutants are the polycyclic aromatic hydrocarbons
(PAHs). Zheng et al. [99] investigated the effect of
PAHs in soil on the expression of TCTP in the earthworm Eisenia fetida and found that it was upregulated by benzopyrene, but down-regulated by
phenanthrene. The effect of anti-cancer drugs on
TCTP levels was discussed earlier.

2. Mechanisms Involved in Regulation of Cellular TCTP
Levels
Whilst TCTP was originally discovered as a translationally regulated protein, it is now overwhelmingly clear that
regulation of cellular TCTP levels may occur at several levels of gene expression and through a range of mechanisms.
This is not surprising, given the variety of stresses or stimulatory signals that have been described to regulate TCTP
levels, and considering the velocity and extent of alteration
of cellular TCTP levels. Moreover, this is well in line with
observations published for other anti-apoptotic or stress proteins, which are also regulated at multiple levels. Here, I will
focus on the major mechanisms known to-date to be involved in TCTP regulation.
• Gene Regulation at the Transcriptional Level
The most detailed studies on gene structure and transcriptional regulation of TCTP synthesis were published by the
Thiele laboratory in Berlin. Initially, they described the gene
structure and upstream promoter sequences of the TCTP
gene from rabbit and humans and established that these regions contain several promoter elements that are wellconserved in mammals. They also showed that, as a whole,
this upstream region exhibits a strong promoter activity
[100]. In a second report, the group characterised various
features of TCTP mRNAs. Typically, cells generate two
forms of this mRNA that differ in the length of their 3'untranslated regions. These were found to be transcribed in
all rabbit and human tissues investigated, but at a considerable range of overall quantity and ratio of expression [73].
This paper also characterises four of the numerous
processed, intronless pseudogenes of TCTP in the rabbit
genome. This earlier work is summarised in our previous review article [8]. A similar paper, characterising the genomic
structure and several pseudogenes of the mouse TCTP gene,
was published at the same time by the Telerman group [101].
Additional evidence for transcriptional regulation of
TCTP levels under specific physiological conditions came
from other publications, such as Stuerzenbaum et al. [92],
who found extreme differences in TCTP mRNA levels in
earthworms exposed to soils polluted with specific heavy
metals, as discussed above. Xu et al. [44] reported both transcriptional and translational regulation of TCTP levels under
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Ca++-stress situations in COS-7 cells. Bonnet et al. [102]
studied genes that are specifically regulated under ammonium starvation in the fission yeast S. pombe, which leads to
growth arrest and cell cycle exit. They found that the genes
for ribosomal protein rpS6 and TCTP are repressed under
this condition, and that their expression is co-ordinately
regulated in many different growth conditions. Under ammonium starvation, transcriptional inhibition of these genes
was regulated either by the PKA pathway and/or by the
Wis1/MAP kinase pathway [102]. Oikawa et al. [98] showed
that the dioxin-stimulated expression of TCTP (HRF)
mRNA occurs via an aryl hydrocarbon receptor (AhR)dependent pathway.
These were the first reports on specific signalling pathways/transcription factors that are involved in transcriptional
activation of the TCTP gene. A further study of the promoter
region of the human TCTP gene, again by the Thiele group,
revealed that transcriptional regulation of TCTP occurs by
PKA signalling, via activation of members of the CREB
family of transcription factors [103], which is consistent with
the conclusions obtained from fission yeast mutants mentioned above [102]. Other transcription factors recently
shown to directly regulate the transcription of the tpt-1
(TCTP) gene include CHD1L [24] and the tumour suppressor protein p53 [59].
Another paper from the Thiele laboratory investigated
both transcriptional and post-transcriptional regulation of the
tpt-1 (TCTP) gene in mammalian cell lines under a variety of
conditions known to result in alterations of TCTP levels
[88]. Phorbol ester, forskolin, dioxin, cobalt, nickel and, to
the highest extent, copper induced TCTP expression at both
the mRNA and protein levels. The strong copper-dependent
transcriptional activation was transmitted by a metalresponse element residing in the tpt-1 promoter. In contrast,
the more moderate effects by cobalt and nickel where mediated by mRNA stabilisation, rather than by transcriptional
activation [88].
• Translational Regulation of TCTP Levels
Early evidence for translational regulation of TCTP
emerged from the following observations: 1. The seruminduced increase in the rate of TCTP (P23 or Q23) synthesis
clearly preceded that of transcriptionally regulated proteins,
and it was not inhibited by actinomycin D [1, 3]. 2. The
mRNA of TCTP (P21) was found abundantly in untranslated
cytoplasmic mRNP particles [2], which are presumed to be a
cytoplasmic ‘reserve pool’ of untranslated mRNAs.
At that time, knowledge about translational control
mechanisms was just beginning to emerge. In the early nineties, the importance of the cap-binding initiation factor
eIF4E for the efficient translation of otherwise poorly translated mRNAs was just being appreciated. Such mRNAs
typically code for proteins, which are involved in the cell
cycle and cancer (reviewed in [104]). Since TCTP (P23) was
described as growth-induced translationally controlled protein, we investigated whether it might be one of the mRNAs
specifically regulated by eIF4E. We made use of eIF4E
overexpressing fibroblasts to demonstrate that the rate of
synthesis of TCTP is indeed correlated with eIF4E levels/activity in the cell [105].
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Since this publication, important additional elements of
the signalling pathways and mechanisms that regulate protein synthesis have been elucidated. It has become clear that
the mammalian target of rapamycin complex 1, mTORC1, is
central to the complex regulatory network for protein synthesis and that eIF4E is an important element of this network,
downstream of mTORC1. The eIF4E binding proteins
(eIF4E-BPs), which normally inhibit eIF4E, are inactivated
through phosphorylation by mTORC1 (reviewed in [65]).
There are two key features of the TCTP mRNA that
make it a prime candidate for an mRNA specifically regulated by mTOR (and eIF4E): 1. As mentioned above, TCTP
mRNA has a 5-terminal oligopyrimidine tract (5’-TOP), the
signature typical for mRNAs coding for proteins that are part
of the translational machinery and are known to be regulated
by mTORC1. 2. We have previously shown that TCTP
mRNA is a highly structured RNA molecule [60], and translation of such mRNAs is particularly dependent on the activity of eIF4E.
For these reasons, we are currently reinvestigating the
mechanisms involved in growth-factor-dependent translational up-regulation of TCTP synthesis; in particular we address the question of the involvement of the mTORC1 pathway. We have now obtained results demonstrating that in
HeLa cells, serum-induced synthesis of TCTP is partially
inhibited by rapamycin, and completely inhibited by inhibitors of mTOR kinase activity and of the protein kinase Akt,
which is upstream of mTORC1. In addition, eIF4E overexpression drives TCTP mRNA from the subpolysomal fraction into actively translating polysomes (U.A. Bommer, V.
Iadevaia and C.G. Proud, unpublished results). These data
indicate that TCTP mRNA behaves like a genuine 5’-TOP
mRNA that is regulated by mTORC1.
Another key regulatory mechanism of translation, which
leads to cell stress-dependent down-regulation of protein
synthesis, involves the phosphorylation of the -subunit
eukaryotic initiation factor eIF2. There are four distinct
eIF2 kinases, which are each activated under specific cell
stress conditions. We have studied the effect of the doublestranded RNA-dependent protein kinase PKR on TCTP
mRNA translation [60] and have shown that the highly structured TCTP mRNA is able to bind to and activate PKR, resulting in its own translational inhibition. We have also
demonstrated that PKR is indeed necessary for the downregulation of TCTP synthesis under specific stress
conditions, such as serum starvation [60] or Ca++-stress conditions [42].
The involvement of these two key regulatory mechanisms in the regulation of intracellular TCTP levels is in line
with corresponding observations for other anti-apoptotic
proteins. For example, it is well established that the synthesis
of proteins like Bcl-XL, Mcl-1 and survivin are regulated
through the mTORC1 pathway and require eIF4E activity for
their translation [106]. Synthesis of Mcl-1 is also downregulated by PKR [107].
• Other Post-Transcriptional Regulatory Mechanisms
Schmidt et al. [88] investigated the mechanisms involved
in the regulation of TCTP by heavy metals, and found that
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the moderate inductive effects by cobalt and nickel are mediated by mRNA stabilisation, whereas the strong inductive
effect by copper was mediated both at transcriptional and
posttranscriptional levels. They speculated that the AUUUA
elements present in the 3’-untranslated region of TCTP
mRNAs might be involved in the regulation of TCTP mRNA
stability. However, these AUUUA elements do not completely match the features of canonical AU-rich elements
(AREs) known to be involved in the destabilisation of cytokine mRNAs, and nobody has this far directly investigated
their importance in TCTP mRNA. Generally, TCTP mRNA
has been found to be fairly stable and abundant in mammalian cells, although the abundance may vary considerably,
depending on the tissue type [73]. Thus, mRNA stability
regulation as potentially effective regulatory mechanism for
TCTP protein levels should be looked at in the context of the
specific tissue and regulatory condition.
There are few reports describing the regulation of TCTP
levels through protein degradation. Kubiak and colleagues
[18] set out to characterise proteins that are specifically degraded in the first embryonic mitosis in Xenopus laevis.
They identified TCTP as one of the proteins that are ubiquitinylated and potentially degraded via the proteasome in this
phase of the cell cycle. Zhang et al. [52] described the interaction of TCTP (fortilin) with the anti-apoptotic protein Mcl1 and demonstrated in Mcl-1 knockdown experiments that
TCTP is stabilised by Mcl-1. The same group reported later
that dehydroartemisinin (DHA), an important anti-malarial
drug, which was previously shown to bind to Plasmodium
falciparum TCTP, binds to and destabilises human TCTP in
a proteasome-dependent manner [86]. This is interesting,
since DHA is also considered an anti-cancer agent [85, 108].
Although the reports on regulated protein degradation of
TCTP are limited and anecdotal so far, it appears that this
type of regulation may occur in a distinct cell cycle phase
and under pro-apoptotic cell stress conditions.
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NOTE ADDED IN PROOF
While this article was in press, a new paper was
published, documenting a novel function for TCTP: Zhang J,
de Toledo SM, Pandey BN, Guo G, Pain D, Hong Lie, and
Azzam EI. Role of the translationally controlled tumor protein
in DNA damage sensing and repair. Proc. Natl. Acad. Sci.
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